page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Penicillin G Aqueous (Pfizerpen)

Category:

  • Antibiotic

Description:

  • Penicillin, Natural

Indications:

  • Meningococcal menigitis/septicemia

  • Actinomycosis

  • Clostridial infections (botulism, gas gangrene and tetanus)

  • Fusopirochetal infections

  • Rat-bite fever

  • Listeria infections

  • Pasteurella infections

  • Erysipeloid endocarditis

  • Diphtheria (adjunct to antitoxin to prevent carrier state)

  • Anthrax

  • Serious streptococcal infections

  • Syphilis (neurosyphilis)

  • Disseminated gonococcal infections

  • Lyme disease (non-FDA approved indication)

Contraindications:

  • None

Precautions:

  • Pregnancy category B

  • Use with caution in patients with penicillin or cephalosporin allergy (5-10% chance of cross-reactivity)

  • Counsel patient to finish all medication to prevent development of resistance

  • Intramuscular injection or continuous IV infusion are preferred routes of administration

  • Dosage modifications are generally only required in patients with severe renal impairment

Adverse Reactions (Side Effects):

  • Hypersensitivity

  • Gastrointestinal: nausea, vomiting, diarrhea

  • Vaginitis

 

Dosage:

Administered by injection (available in powder for injection and premixed/frozen)

  • Meningococcal menigitis/septicemia:

    • Adult: 24 million units per day (1-2 million units q2h)

    • Adult: 200,000-300,000 units/kg/day q2-4h in divided doses for 24 doses total

    • Children: 250,000 units/kg/day divided equally q4h for 7-14 days

  • Actinomycosis:

    • cervicofacial cases: 1-6 million units per day

    • thoracic/abdominal cases: 10-20 million units/day IV q4-6h for 6 weeks

  • Clostridial infections

    • 20 million units/day q4-6h

  • Fusopirochetal infections

    • 5-10 million units/day q4-6h

  • Rat-bite fever

    • Adult: 12-20 million units/day q4-6h for 3-4 weeks

    • Children: 150,000-250,000 units/kg/day divided equally q4h for 4 weeks

  • Listeria infections

    • 15-20 million units/day q4-6h for 2 weeks (menigitis) or 4 weeks (endocarditis)

  • Pasteurella infections

    • 4-6 million units/day q4-6h for 2 weeks

  • Erysipeloid endocarditis

    • 12-20 million units/day q4-6h for 4-6 weeks

  • Diphtheria

    • Adult: 2-3 million units/day q4-6h for 10-12 days

    • Children: 150,000-250,000 units/kg/day divided equally q6h for 7-10 days

  • Anthrax

    • minimum of 5 million units/day, may go up to 12-20 million units/day

  • Serious streptococcal infections

    • Adult: 5-24 million units/day q4-6h

    • Children: 150,000 units/kg/day divided equally q4-6h

  • Syphilis

    • 18-24 millions units/day (3-4 million units q4h) for 10-14 days

  • Disseminated gonococcal infections

    • Adult: 10 million units/day q4-6h

    • Children (<45 kg):

      • arthritis: 100,000 units/kg/day divided into 4 equal doses for 7-10 days

      • menigitis: 250,000 units/kg/day divided equally q4h for 10-14 days

      • endocarditis: 250,000 units/kg/day divided equally q4h for 4 weeks

    • Children (>45 kg):

      • arthritis, menigitis, endocarditis: 10 million units/day divided into 4 equal doses for duration of therapy

  • Lyme disease

    • use oral penicllin V for erythema chronicum migrans

    • 200,000-300,000 units/kg/day IV for 10-14 days

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

Advertise on this site